Hasil Pencarian  ::  Simpan CSV :: Kembali

Abstrak :

Latar belakang: Diffuse large B-cell lymphoma (DLBCL) adalah Limfoma Non Hodgkin (LNH) yang paling banyak dan paling heterogen dengan prevalensi 25 hingga 30% di negara maju dan 42,5% di negara berkembang. Pemeriksaan imunohistokimia dengan kriteria Hans dapat digunakan sebagai pengganti gene-expression profiling (GEP) dan menggolongkan limfoma ini menjadi subtipe germinal centre B-cell like (GCB) dan non-GCB. Penggunaa terapi yang ada saat ini, masih didapatkan 30% hingga 40% kasus DLBCL mengalami kekambuhan atau residif. Ditemukannya ekspresi CD30 pada DLBCL di beberapa penelitian telah membuka peluang alternatif terapi target baru. Tujuan penelitian ini adalah mengetahui ekspresi CD30 pada DLBCL dan perbedaan ekspresinya pada subtipe GCB dan non-GCB.

Bahan dan cara: Penelitian ini menggunakan desain potong lintang. Sampel terdiri atas 50 kasus DLBCL yang terbagi menjadi 25 kasus subtipe GCB dan 25 kasus subtipe non-GCB berdasarkan pemeriksaan imunohistokimia di RSCM tahun 2014 sampai 2017. Dilakukan pulasan CD30 dan penilaian menggunakan persentase dengan nilai cut off positif >0%, >10% dan >20% sel tumor.

Hasil: Ekspresi CD30 positif didapatkan pada 8(16%), 4(8%), 3(6%) dari 50 kasus DLBCL dengan nilai cut off positif >0%, >10%, >20% secara berurutan. Uji Fisher’s exact yang dilakukan mendapatkan ekspresi CD30 pada subtipe GCB dan non-GCB tidak berbeda bermakna dengan nilai p>0,05.

Kesimpulan: Tidak didapatkan perbedaan yang bermakna antara ekspresi CD30 pada DLBCL subtipe GCB dan non-GCB

---

Background: Diffuse large B-cell lymphoma (DLBCL) is the most common and most heterogeneous Non Hodgkin lymphoma (NHL) with  prevalence 25 until 30% in developed countries and 42.5% in developing countries. Immunohistochemical examination using Hans criteria can be used to surogate gene-expression profiling (GEP) and classifies DLBCL as germinal center B-cell like (GCB) and non-GCB subtype. Using recent therapies is still result in 30 to 40% of disease relapse or refractory. Expression of CD30 on DLBCL in several studies has opened up opportunities for new alternative therapeutic targets. The aim of this study is to determine CD30 expression on DLBCL and the difference expression in GCB and non-GCB subtypes.

Materials and methods: This was a cross-sectional study with 50 cases of DLBCL consist of 25 cases of GCB subtypes and 25 cases of non-GCB subtypes based on immunohistochemical examination at RSCM in 2014 until 2017. All cases were stained by CD30 antibody and evaluated using percentage with cut off  value >0%, >10% dan >20% tumor cells. 

Result: Positive CD30 expression was obtained at 8 (16%), 4 (8%), 3 (6%) out of 50 DLBCL cases with cut off values >0%, >10%, >20% respectively. The Fisher's exact test showed no significant difference of CD30 expression between GCB and non-GCB subtypes with p value >0.05.

Conclusion: There is no significant difference in the expressions of CD30 between DLBCL GCB and non-GCB subtypes.

 

Abstrak :
ABSTRACT
Background: the expression of CD30, CD15, CD50, and PAX5 are used to help in confirming diagnosis of HL and sALCL; however data on the proportion of these markers have not been available. The study was aimed to identify the proportion of CD30, CD15, CD50 and PAX5 expressions and characteristics of patients with HL and sALCL at Dharmais National Cancer Center Hospital between 2005 and 2015. Methods: a retrospective observational study was conducted using data from medical records and histopathological results of HL and sALCL adult patients who sought treatment at the hospital between 2005 and 2015. Immunohistochemistry (IHC) examinations were performed and data on the proportion of positive CD30, CD15, CD50, and PAX5 expressions were analyzed descriptively.Results: a total of 45 patients were recruited in this study, with the majority (42 patients, 93.3%) were HL patients and only 6.7% were sALCL patients. The median age of HL patients was younger than sALCL patients; 35 (18-72 years old) versus 54 (49-61 years old). Moreover, the immunohistochemistry examination demonstrated that the positive CD15, CD30, CD50, and PAX5 expressions were found respectively in 37.5%, 88.9%, 31.2%, and 31.2% patients with HL; while in patients with sALCL, in spite of their small sample size, positive CD30, CD15, CD50 and PAX5 expressions were found in 100%; 66,7%; 50%; and 50%, respectively. Overall, CD15, CD50, and PAX5 positive expressions were found in 39.5%, 32.4%, and 32.4% patients who had HL and sALCL; while positive expression of CD30 was found in 89.5% of them. Conclusion: present study shows that almost 90% patients have positive CD30 expression;Â while the positive expressions of CD15, CD50, and PAX5 are found in less than 40% patients. It indicates that CD30 is an important diagnostic marker for HL and sALCL and it may improve treatment strategy.